JP Morgan Chase
EIDX

JP Morgan Chase’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

JP Morgan Chase’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,096
Closed -$671K – 6560
2020
Q4 		$671K Buy
5,096
+1,019
+25% +$90K ﹤0.01% 4205
2020
Q3 		$204K Buy
4,077
+202
+5% +$9.08K ﹤0.01% 4351
2020
Q2 		$185K Sell
3,875
-12,517
-76% -$582K ﹤0.01% 4300
2020
Q1 		$803K Buy
16,392
+11,435
+231% +$583K ﹤0.01% 3547
2019
Q4 		$284K Buy
4,957
+286
+6% +$14.2K ﹤0.01% 4537
2019
Q3 		$168K Buy
4,671
+1,631
+54% +$63.7K ﹤0.01% 4706
2019
Q2 		$86K Sell
3,040
-907
-23% -$24.6K ﹤0.01% 4985
2019
Q1 		$93K Buy
3,947
+2,093
+113% +$33.6K ﹤0.01% 4910
2018
Q4 		$26K Sell
1,854
-14,858
-89% -$187K ﹤0.01% 5275
2018
Q3 		$167K Buy
+16,712
New +$275K ﹤0.01% 4754

JP Morgan Chase's EIDX Position: Q1 2021 in Review

JP Morgan Chase sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 5,096 shares — an estimated $671K sold.

JP Morgan Chase first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $803K in Q1 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • JP Morgan Chase reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • JP Morgan Chase sold 5,096 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $671K.
  • JP Morgan Chase first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • JP Morgan Chase's Eidos Therapeutics, Inc. Common Stock position peaked at $803K in Q1 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on JP Morgan Chase's 13F filing for Q1 2021, filed 12 May 2021.